TET2 and acute promyelocytic leukemia: Cases with an APL-like phenotype frequently display dim or absent CD13 expression (68% of cases), a higher likelihood of CD56 positivity (40% of cases), and are more likely to harbor mutations in TET2 or IDH1/2 and less likely in DNMT3A. This subtype is associated with longer relapse-free and overall survival compared to non-APL-like cases with myeloid differentiation [15].